Exosome & EV CDMOs — Ranked by Signal Score · 2026

· updated as new inspection, certificate, and trial data enters the platform

Exosome / Extracellular Vesicle manufacturers on CDMO Signal: 6 listed, 6 with a Signal Score. Fewer than three are fully evidenced (all four score pillars and at least one ClinicalTrials.gov match), so this page does not name a top three. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-10-16. Methodology.

6
CDMOs tracked
6
Fully scored

Exosome and extracellular vesicle (EV) CDMOs manufacture next-generation delivery vehicles for RNA, proteins, and small molecules. As an emerging modality, the field is still standardizing cell-source, isolation, and potency methods.

Choosing an exosome CDMO turns on cell-source and culture scale, isolation method (TFF, chromatography), characterization, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

Last updated 2026-10-16. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing contract manufacturers only.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
EA
Singapore, Singapore
63.0 — — None on file — —
2
CK
Cambridge, MA
Also makes its own products
60.3 — — None on file — 16 programs
3
EXO
Liège, Belgium
56.5 — — None on file — —
4
EV
Oxford, United Kingdom
Also makes its own products
56.5 — — None on file — —
5
EP
Melbourne, Australia
56.5 — — None on file — —
How we score CDMOs →

What to evaluate in a Exosome / Extracellular Vesicle CDMO

Cell source & scale
Confirm the producer cell source and whether culture is suspension-adapted for the volumes EV yields demand.
Isolation & purification
Isolation method (tangential-flow filtration, chromatography) drives yield, purity, and scalability. Ask how it performs at your target scale.
Characterization & potency
EV characterization (particle count, size, cargo, identity) and potency assays are still maturing — look for established, qualified methods.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

Exosome / Extracellular Vesicle CDMOs — Frequently Asked Questions

What should I look for in an exosome CDMO?
Confirm cell source and scalable culture, a robust isolation method (TFF or chromatography), qualified characterization and potency analytics, and a clean FDA and EMA/MHRA record.
Is exosome manufacturing standardized?
Not yet fully — cell-source, isolation, and potency methods are still maturing across the field, so a CDMO's specific platform and analytics maturity matter more than in established modalities.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Save this Exosome shortlist
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.
Related modalities
mRNA / LNP CDMOs Cell Therapy CDMOs Biologics / mAb CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy Viral Vector